 "Vivek Chaand Sehgal resigns as director from Sun Pharmaceutical board")
Drug firm Sun Pharmaceutical Industries on Friday said Vivek Chaand Sehgal has resigned as an independent director of the company with effect from September 1.
Sehgal is the Chairman of Samvardhana Motherson Group (SMG).
"Mr Sehgal has stated in his resignation letter that the resignation is purely because of his personal reasons and other pre-occupations only, and confirmed that there is no other material reason for his resignation," Sun Pharma said in a regulatory filing.
The resignation of Sehgal effective from September 1, 2021, is taken on record and accepted by the Board of Directors of the company..., it added.
Shares of Sun Pharmaceutical Industries closed at Rs 789.15 per scrip on BSE, down 0.12 per cent from its previous close.
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app